Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.



Published on

Published in: Health & Medicine


  2. 2. Definition A systemic skeletal disease characterized by low bone mass and micro architectural deterioration of bone tissue leading to bone fragility and susceptibility to fracture
  3. 3. Who Gets Osteoporosis? Immobilization Hypogonadal states Endocrine disorders Malnutrition, parenteral nutrition and malabsorption rheumatologic disorders Renal insufficiency Hematologic disorders Several inherited disorders
  4. 4. Osteoporosis Mechanisms causing osteoporosis  Imbalance between rate of resorption and formation  Failure to complete stages of remodeling Types of osteoporosis  Type I  Type II  Secondary
  5. 5. Osteoporosis - Types Postmenopausal osteoporosis (type I)  Caused by lack of estrogen  Causes PTH to overstimulate osteoclast Age-associated osteoporosis (type II)  Bone loss due to increased bone turnover  Malabsorption  Mineral and vitamin deficiency
  6. 6. Classification Primary  Postmenopausal  Bone loss – 2-3% per year of total bone mass  Most common fx: vertebral, distal forearm  Age related – 3rd decade of life starts slow decline in bone mass at rate of 0.5-1% per year  Most common types of fx: hip and radius  F>M Secondary
  7. 7. Secondary OsteoporosisDisease states Acromegaly  Multiple myeloma Addison’s disease  Multiple sclerosis Amyloidosis  Rheumatoid arthritis Anorexia  Sarcoidosis COPD  Severe liver dz, esp. Hemochromatosis PBC Hyperparathyroidism  Thalessemia Lymphoma and  Thyrotoxicosis leukemia Malabsorption states
  8. 8. Secondary OsteoporosisDrugs Aluminum Anticonvulsants Excessive thyroxine Depo Provera (decreased bone mass reversible after stopping medication) Glucocorticoids GnRH agonists Heparin Lithium
  9. 9. Diagnosing Osteoporosis Outcome of interest: Fracture Risk! Outcome measured (surrogate): BMD  Key: Older women at higher risk of fracture than younger women with SAME BMD!  Other factors: risk of falling, bone fragility not all related to BMD
  10. 10. Prevalence of osteoporosis Osteopenia Osteoporosis Female 37-50% 13-18% Age > 50 year Male 28-47% 3-6% Age > 50 year
  11. 11. Incidence of osteoporotic Fx
  12. 12. Incidence of osteoporotic Fx
  13. 13. Diagnosis of Osteoporosis Physical examination Measurement of bone mineral content• Dual X-ray absorptiometry (DXA)• Ultrasonic measurement of bone• CT scan• Radiography
  14. 14. Physical examination Osteoporosis Vertebral fracture Height loss Arm span-height Body weight difference Kyphosis Wall- occiput Humped back distance Tooth loss Rib-pelvis distance Skinfold thickness Grip strength
  15. 15. Physical examination
  16. 16. Physical examination No single maneuver is sufficient to rule in orrule out osteoporosis or vertebral fracturewithout further testing
  17. 17. Diagnosing Osteoporosis Laboratory Data  Limited value in diagnosis  Markers of bone turnover (telopeptide) more useful in monitoring effects of treatment than in diagnosis  Helpful to exclude secondary causes  Hyperthyroidism  Hyperparathyroidism  Estrogen or testosterone deficiency  Malignancy  Multiple myeloma  Calcium/Vitamin D deficiency
  18. 18. Work-upScreen for secondary causes  Serum calcium, phosphorus, alk phos  PTH if calcium is high (hyperparathyroidism)  25-hydroxyvitamin D if low ca, low phos and high alk. phos (osteomalacia)  Thyroid function tests (thyrotoxicosis)  SPEP, UPEP (multiple myeloma)  24-hour urinary calcium (hyper or hypo calciuria)  Serum testosterone (hypogonadism)
  19. 19. Methods to evaluate for osteoporosis Quantitative Ultrasonography Quantitative computed tomography Dual Energy X-ray Absorptiometry (DEXA)  ?”gold standard”  Measurements vary by site  Heel and forearm: easy but less reliable (outcome of interest is fracture of vertebra or hip!)  Hip site: best correlation with future risk hip fracture  Vertebral spine: predict vertebral fractures; risk of falsely HIGH scores if underlying OA/osteophytes
  20. 20. Dual X-ray absorptiometry 2-dimensional study BMD = Amount of mineral Area Accuracy at hip > 90% Low radiation exposure Error in Osteomalacia Osteoarthritis Previous fracture
  21. 21. How to interpret the BMD T score: standard deviation of the BMD from the average sex matched 35-year-old Z score: less used; standard deviation score compared to age matched control For every 1 decrease in T score, double risk of fracture 1 SD decrease in BMD = 14 year increase in age for predicting hip fracture risk Regardless of BMD, patients with prior osteoporotic fracture have up to 5 times risk of future fracture!
  22. 22. Dual X-ray absorptiometry BMD compare with T score young adult femaleNormal < 1 SD below >/= -1Low bone mass ( Osteopenia ) 1-2.5 SD below < -1 > -2.5Osteoporosis >/= 2.5 SD below </= -2.5Severe osteoporosis >/= 2.5 SD below PLUS Fracture
  23. 23. Dual X-ray absorptiometry WHO criteria - Hip BMD Normal Low bone mass (Osteopenia) Osteoporosis Severe osteoporosis
  24. 24. Osteoporosis Can Be Assessed byDXA Relative Risk of Fracture DXA-assessed content is a per SD Decrease in BMD proven effective method for 3 assessing osteoporosis 2.5 related fracture risk. Relative Risk 2 Population surveys and Forearm 1.5 Hip research studies demonstrate 1 Spine a decrease in bone density 0.5 measured by DXA predicts 0 fracture at specific sites. m l p s ra ite Hi ar b lS re rte Fo Al Ve
  25. 25. Ultrasonic measurement Broad-band ultrasound attenuation No radiation exposure Cannot be used for diagnosis Preferred use in assessment of fracture risk
  26. 26. The calcaneus is the most common skeletal site for quantitative ultrasound assessment because -It has a high percentage of trabecular bone that is replaced more often than cortical bone, providing early evidence of metabolic change. -Also, the calcaneus is fairly flat and parallel, reducing repositioning errors.
  27. 27. The McCue CUBA: UltrasonometryTechnology That Can Assess Osteoporosis
  28. 28. Heel BUA is Significantly Lower inSubjects With Future Hip Fracture. 60 BUA (dB/sq MHz) 50 40 30 20 10 0 Fracture No FractureSubjects who developed hip fracture showed significantly (p<0.001) lowerheel BUA results.
  29. 29. CT scan True volumetric study Quantitative Computed Tomography (QCT) utilizes CT technology to detect low bone mass and monitors the effects of therapy in patients undergoing treatment. It is a fast, non-invasive exam that detects low bone mass earlier and more accurately than other bone density exams
  30. 30. QCT in a 62-year-old female patient
  31. 31.  The trabecular BMD is indicated as the most important parameter, and interpreted using the Felsenberg classification, based on the following cut-off values: Normal BMD > 120 mg/cc Osteopenia < 120 mg/cc Osteoporosis < 80 mg/cc Very high fracture risk < 50 mg/cc
  32. 32. Advantages over DXA: Ability to separate cortical and trabecular bone Provides true volumetric density in units of mg/cc No errors due to spinal degenerative changes or aortic calcification
  33. 33. Clinicians and researchers favor DXA because-scanners are readily available and relativelyinexpensive.-The radiation dose is negligible-The T-score scale, defined by the WHO specifically forDXA, provides a standardized classification.
  34. 34. Plain radiography Low sensitivity High availability Subclinical vertebral fracture is a strong risk factor for subsequent fractures at new vertebral site and other sites
  35. 35. The main radiographic features of generalizedosteoporosis are cortical thinning and increasedradiolucency
  36. 36. Singh Index The Singh index describes the trabecular patterns in the bone at the top of the thighbone (femur). X-rays are graded 1 through 6 according to the disappearance of the normal trabecular pattern. Studies have shown a link between a Singh index of less than 3 and fractures of the hip, wrist, and spine.
  38. 38. Assessment of fracture risk DXA and quantitative ultrasound Clinical risk factors Markers of bone turnover Bone formation Bone resorption
  39. 39. Assessment of fracture risk DXA Risk of fracture = 1.5-3.0 for each SD decrease in BMD Low sensitivity ( comparable to BP in predicting stroke ) Screening is not recommended Quantitative ultrasound Risk of fracture = 1.5-2.0 for each SD decrease in BMD
  40. 40. Assessment of fracture risk Markers of bone turnoverBone formation markers Bone resorption markers Alkaline phosphatase Hydroxyproline Bone isoenzyme AP Pyridinium crosslinks & Osteocalcin associated peptides Procollagen propeptides of type I collagen
  41. 41. Assessment of fracture riskMarkers of bone turnover Associated with osteoporotic fracture independent of bone density 2-Fold increase in fracture risk ? Combined approach with BMD to increased sensitivity
  42. 42. Assessment of fracture riskClinical risk factors for fracture Low bone mass History or falls Impaired cognition ( plus medication adverse effect ) Low physical function Presence of environmental hazards Long hip axis length Chronic glucocorticoid use Existing fracture Chronic use of seizure medications Renal, hepatic, thyroid, parathyroid, malabsorptive disorder, vitamin D deficiency, MM and local neoplasia to be ruled out National Osteoporosis Foundation 1998
  43. 43. Assessment of fracture riskPredictors of low bone mass Female Advanced age Gonadal hormone deficiency ( estrogen or testosterone ) White race Low body weight & BMI Family history of osteoporosis Low calcium intake Smoking / excessive alcohol intake Low level of physical acitivity Chronic glucocorticoid use History of fracture National Osteoporosis Foundation 1998
  44. 44. When to Measure BMD inPostmenopausal Women All women 65 years and older Postmenopausal women <65 years of age:  Ifresult might influence decisions about intervention  One or more risk factors  History of fracture
  45. 45. When Measurement of BMD Is NotAppropriate Healthy premenopausal women Healthy children and adolescents Women initiating ET/HT for menopausal symptom relief (other osteoporosis therapies should not be initiated without BMD measurement)
  46. 46. THANK YOU